Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.70 |
| ▸ | RAB9A | P51151 | 6/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.70 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.70 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.70 |
| ▸ | RELA | Q04206 | 4/20 | 0.70 |
| ▸ | PKM | P14618 | 3/20 | 0.70 |
| ▸ | TP53 | P04637 | 3/20 | 0.70 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | HTR2C | P28335 | 6/20 | 0.54 |
| ▸ | HTR2A | P28223 | 5/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4863733 | 0.91 | TP53 (0.58) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL3029174 | 0.89 | NPC1 (0.70) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL382910 | 0.83 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL4869045 | 0.81 | TP53 (0.58) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL29962924 | 0.80 | BRD4 (0.51) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL2851575 | 0.80 | RAB9A (0.64) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL4867584 | 0.80 | BRD4 (0.52) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL3461334 | 0.79 | BRD4 (0.56) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL3454628 | 0.79 | HPGD (0.68) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4870796 | 0.76 | TP53 (0.59) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120196884-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORPORATION (FI) | 2012-08-02 | — | — | US | disclosed |
| US-20120196884-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORPORATION (FI) | 2012-08-02 | — | — | US | disclosed |
| US-8232312-B2 | Substituted arylsulphonylglycines, the preparation thereof and the use thereof as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-31 | — | — | US | disclosed |
| US-8232312-B2 | Substituted arylsulphonylglycines, the preparation thereof and the use thereof as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-31 | — | — | US | disclosed |
| WO-2010146236-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORP. (FI) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010146236-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORP. (FI) | 2010-12-23 | — | — | WO | disclosed |
| US-20100130557-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-27 | — | — | US | disclosed |
| US-20100130557-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-27 | — | — | US | disclosed |
| WO-2008113760-A2 | ARYLSULPHONYGLYCINE DERIVATIVES AS SUPPRESSORS OF THE INTERACTION OF GLYCOGEN PHOSPHORYLASE A WITH THE GL SUBUNIT OF GLYCOGEN-ASSOCIATED PROTEIN PHOSPHATASE 1 (PPL) FOR THE TREATMENT OF METABOLIC DISORDERS, PARTICULARY DIABETES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130557-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | PYGL, PYGM, G6PC1 | NPC1 3685/4885RAB9A 1862/4885SMN1; SMN2 2730/4885 |
| US-20120196884-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | ITGA1, ITGB1, ITGA2B | NPC1 4603/4885RAB9A 2294/4885SMN1; SMN2 3298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.